1. (a) All OTPs shall assess each individual for appropriateness for admission, ensuring the individual is placed in the least restrictive level of care.
2. (b) OTPs shall require each person served to undergo an initial medical examination. The initial medical examination shall be comprised of two parts:
3. (1) A screening examination to ensure that the person served meets criteria for admission and that there are no contraindications to treatment with MOUD; and
4. (2) A full history and examination, to determine the individual's broader health status, with lab testing as determined to be required by an appropriately licensed practitioner. An individual's refusal to undergo lab testing for co-occurring physical health conditions should not preclude them from access to treatment, provided such refusal does not have potential to negatively impact treatment with medications.
5. (c) If there are no contraindications, an individual may commence treatment with MOUD after the screening examination has been completed. Both the screening examination and full examination must be completed by an appropriately licensed practitioner. If the licensed practitioner is not an OTP practitioner, the screening examination must be completed no more than seven (7) days prior to OTP admission. Where the examination is performed outside of the OTP, the written results and narrative of the examination, as well as available lab testing results, must be transmitted, consistent with applicable privacy laws, to the OTP, and verified by an OTP practitioner.
6. (d) A full in-person physical examination, including the results of serology and other tests that are considered to be clinically appropriate, must be completed within fourteen (14) calendar days following an individual’s admission to the OTP. The full exam can be completed by a non-OTP practitioner, if the exam is verified by a licensed OTP practitioner as being true and accurate and transmitted in accordance with applicable privacy laws.
7. (e) Serology testing and other testing as deemed medically appropriate by the licensed OTP practitioner based on the screening or full history and examination, drawn not more than thirty (30) days prior to admission to the OTP, may form part of the full history and examination.
8. (f) The screening and full examination may be completed via telehealth for those individuals being admitted for treatment at the OTP with either buprenorphine or methadone, if a practitioner or primary care provider determines that an adequate evaluation can be accomplished via telehealth. When using telehealth, the following caveats apply:
9. (1) In evaluating patients for treatment with schedule II medications (such as Methadone), audio-visual telehealth platforms must be used, except when not available to the patient. When not available, it is acceptable to use audio-only devices, but only when the patient is in the presence of a licensed practitioner who is registered to prescribe (including dispense) controlled medications. The OTP practitioner shall review the examination results and order treatment medications as indicated.
10. (2) In evaluating patients for treatment with schedule III medications (such as Buprenorphine) or medications not classified as a controlled medication (such as Naltrexone), audio-visual or audio only platforms may be used. The OTP practitioner shall review the examination results and order treatment medications as indicated.

11. (g) Compliance with 450:70-3-5 may be determined by:

    1. (1) A review of policies and procedures,
    2. (2) Treatment records, and
    3. (3) Other facility documentation.

Added at 24 Ok Reg 2634, eff 7-12-07

Amended at 26 Ok Reg 1303, eff 7-1-09

Amended at 30 Ok Reg 1425, eff 7-1-13

Amended at 34 Ok Reg 1830, eff 10-1-17

Amended at 40 Ok Reg 1079, eff 9-15-23

Amended at 42 Ok Reg, Number 20, effective 9-1-25